Lantern Pharma Inc.作为AI驱动肿瘤药物研发领域的先驱企业，已成功获得美国食品药品监督管理局（FDA）的试验许可。这项关键批准将推动一项针对三阴性乳腺癌（TNBC）的创新药物组合方案进入1B/2期临床试验阶段。研究将深入评估药物LP-184与DNA损伤反应抑制剂olaparib的联合疗效。此次里程碑事件凸显了Lantern Pharma的RADR®平台潜力——通过整合人工智能模块，该平台精准预测并优化癌症治疗结果。利用基因组学、转录组学和临床数据的多维分析，RADR®旨在提升治疗精确度、显著改善患者响应率，同时有效降低毒性风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.